All In Biotech

Free tool

FAERS Monitor: Cleocin Phosphate

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 050441 or its brand name (Cleocin Phosphate, Clindamycin Phosphate). Reports on generic versions are filed under their own applications.

Reports

3,596

Serious

2,284

64% of reports

Hospitalization

1,058

Death reported

270

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective373
  • rash259
  • drug hypersensitivity231
  • off label use228
  • diarrhoea192
  • nausea190
  • fatigue171
  • pruritus169
  • pain164
  • condition aggravated135
  • dyspnoea116
  • headache114
  • pyrexia110
  • product use in unapproved indication109
  • vomiting103

Reports by year received

View as table
YearReports
200419
200553
200659
200714
200820
200943
201086
201166
201299
2013102
2014103
2015125
2016246
2017184
2018237
2019281
2020210
2021194
2022288
2023305
2024287
2025309
2026264

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,563 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug hypersensitivitySignal2317.06.21,189
rashSignal2593.53.1464
condition aggravatedSignal1352.62.2133
product use in unapproved indicationSignal1092.62.1104
pruritusSignal1692.62.2164
pyrexia1101.91.544
diarrhoea1921.71.562
drug ineffective3731.71.5103
pain1641.61.334
off label use2281.51.342
nausea1901.41.223
fatigue1711.31.111
vomiting1031.31.16
dyspnoea1161.21.04
headache1141.10.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.